Trial Profile
A Phase II Multicenter, Randomized, Double-Blind, Two-Stage Clinical Trial to Evaluate the Efficacy and Safety of MK0594 in Patients With Alcohol Dependence
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 20 May 2021
Price :
$35
*
At a glance
- Drugs Serlopitant (Primary)
- Indications Alcoholism
- Focus Adverse reactions; Therapeutic Use
- Sponsors Merck Sharp & Dohme; VYNE Therapeutics
- 24 Dec 2014 New trial record